Driehaus Capital Management LLC Acquires 8,547 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Driehaus Capital Management LLC lifted its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 7.8% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 118,746 shares of the company’s stock after purchasing an additional 8,547 shares during the period. Driehaus Capital Management LLC owned about 0.42% of Krystal Biotech worth $21,807,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. TD Asset Management Inc raised its stake in Krystal Biotech by 82.7% during the 4th quarter. TD Asset Management Inc now owns 40,962 shares of the company’s stock worth $5,082,000 after acquiring an additional 18,542 shares during the period. Capstone Investment Advisors LLC bought a new stake in Krystal Biotech during the 4th quarter worth approximately $303,000. Rafferty Asset Management LLC raised its stake in Krystal Biotech by 17.0% during the 4th quarter. Rafferty Asset Management LLC now owns 84,021 shares of the company’s stock worth $10,424,000 after acquiring an additional 12,215 shares during the period. CenterBook Partners LP raised its stake in Krystal Biotech by 23.6% during the 4th quarter. CenterBook Partners LP now owns 5,335 shares of the company’s stock worth $662,000 after acquiring an additional 1,020 shares during the period. Finally, S Squared Technology LLC raised its stake in Krystal Biotech by 1.8% during the 4th quarter. S Squared Technology LLC now owns 110,215 shares of the company’s stock worth $13,673,000 after acquiring an additional 2,000 shares during the period. Institutional investors own 86.29% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on KRYS. Stifel Nicolaus raised their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. HC Wainwright increased their price objective on shares of Krystal Biotech from $200.00 to $221.00 and gave the company a “buy” rating in a report on Wednesday, August 28th. Chardan Capital increased their price objective on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a report on Monday, August 5th. Finally, Citigroup reaffirmed a “neutral” rating and set a $204.00 price objective (up from $195.00) on shares of Krystal Biotech in a report on Tuesday, August 6th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Krystal Biotech currently has an average rating of “Buy” and an average target price of $196.75.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the transaction, the insider now directly owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 14.10% of the stock is currently owned by insiders.

Krystal Biotech Stock Performance

KRYS stock opened at $177.14 on Friday. The firm has a fifty day moving average price of $192.47 and a 200 day moving average price of $179.64. Krystal Biotech, Inc. has a fifty-two week low of $93.95 and a fifty-two week high of $219.34. The firm has a market cap of $5.06 billion, a PE ratio of 94.73 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, August 5th. The company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.03. Krystal Biotech had a net margin of 63.73% and a return on equity of 1.99%. The firm had revenue of $70.28 million during the quarter, compared to analyst estimates of $65.27 million. During the same period last year, the firm posted ($1.25) earnings per share. Krystal Biotech’s revenue for the quarter was up 70283900.0% compared to the same quarter last year. On average, equities analysts predict that Krystal Biotech, Inc. will post 3.13 EPS for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).